title: Phase II Study of Docetaxel, Nedaplatin, and 5-Fluorouracil Combined Chemotherapy for Advanced Esophageal Cancer.
abstract: BACKGROUND
  We performed a prospective, multi-institutional, phase-II, clinical trial of a docetaxel, nedaplatin, and 5-fluorouracil (DNF) regimen in patients with unresectable esophageal cancer. Our goal was to determine the efficacy and feasibility of this DNF protocol.
  
  
  METHODS
  Thirty-four patients with unresectable esophageal cancer were enrolled and received DNF therapy. The DNF regimen was repeated every 4 weeks for up to 8 weeks, based on the following recommended doses: docetaxel, 60 mg/m(2) (day 1); nedaplatin, 70 mg/m(2) (day 1); and 5-fluorouracil, 700 mg/m(2) (days 1-5). The primary endpoint was the response rate. The secondary endpoints were overall survival and chemotherapy toxicities.
  
  
  RESULTS
  The complete response rate and response rate were 5.9 and 47.1 %, respectively. The 2-year overall survival rate and progression-free survival rate were 44.3 and 27.3 %, respectively. The median survival time was 594 days. The median progression-free time was 277 days. No treatment-related deaths occurred. Thirty patients (30/34) with grade 3, 4 neutropenia improved relatively quickly with administration of granulocyte colony-stimulating factor.
  
  
  CONCLUSIONS
  DNF combination chemotherapy is a useful regimen with relatively minor adverse events and may serve as an effective protocol in patients with unresectable esophageal cancer.
authors.affiliation: Department of General Surgical Science (Surgery 1), Gunma University Graduate School, Maebashi, Gunma, Japan. tatsuyamiyazaki@gunma-u.ac.jp.
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Miyazaki
authors.affiliation: Department of General Surgical Science (Surgery 1), Gunma University Graduate School, Maebashi, Gunma, Japan.|Department of Gastroenterological Surgery, Gunma Prefectural Cancer Center, Ota, Japan.
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Ojima
authors.affiliation: Department of General Surgical Science (Surgery 1), Gunma University Graduate School, Maebashi, Gunma, Japan.|Department of Surgery, Gunma Chuo Hospital, Maebashi, Gunma, Japan.
authors.forename: Minoru
authors.initials: M
authors.lastname: Fukuchi
authors.affiliation: Department of General Surgical Science (Surgery 1), Gunma University Graduate School, Maebashi, Gunma, Japan.|Department of Surgery, Isesaki Municipal Hospital, Isesaki, Gunma, Japan.
authors.forename: Makoto
authors.initials: M
authors.lastname: Sakai
authors.affiliation: Department of General Surgical Science (Surgery 1), Gunma University Graduate School, Maebashi, Gunma, Japan.
authors.forename: Makoto
authors.initials: M
authors.lastname: Sohda
authors.affiliation: Department of General Surgical Science (Surgery 1), Gunma University Graduate School, Maebashi, Gunma, Japan.
authors.forename: Naritaka
authors.initials: N
authors.lastname: Tanaka
authors.affiliation: Department of General Surgical Science (Surgery 1), Gunma University Graduate School, Maebashi, Gunma, Japan.
authors.forename: Shigemasa
authors.initials: S
authors.lastname: Suzuki
authors.affiliation: Department of General Surgical Science (Surgery 1), Gunma University Graduate School, Maebashi, Gunma, Japan.|Department of Surgery, Isesaki Municipal Hospital, Isesaki, Gunma, Japan.
authors.forename: Keisuke
authors.initials: K
authors.lastname: Ieta
authors.affiliation: Department of General Surgical Science (Surgery 1), Gunma University Graduate School, Maebashi, Gunma, Japan.|Department of Surgery, Gunma Chuo Hospital, Maebashi, Gunma, Japan.|Department of Surgery, Isesaki Municipal Hospital, Isesaki, Gunma, Japan.
authors.forename: Kana
authors.initials: K
authors.lastname: Saito
authors.affiliation: Department of General Surgical Science (Surgery 1), Gunma University Graduate School, Maebashi, Gunma, Japan.|Department of Gastroenterological Surgery, Gunma Prefectural Cancer Center, Ota, Japan.
authors.forename: Akihiko
authors.initials: A
authors.lastname: Sano
authors.affiliation: Department of General Surgical Science (Surgery 1), Gunma University Graduate School, Maebashi, Gunma, Japan.
authors.forename: Takehiko
authors.initials: T
authors.lastname: Yokobori
authors.affiliation: Department of General Surgical Science (Surgery 1), Gunma University Graduate School, Maebashi, Gunma, Japan.
authors.forename: Takanori
authors.initials: T
authors.lastname: Inose
authors.affiliation: Department of Surgery I, Dokkyo Medical University, Tsuga-gun, Tochigi, Japan.
authors.forename: Masanobu
authors.initials: M
authors.lastname: Nakajima
authors.affiliation: Department of Surgery I, Dokkyo Medical University, Tsuga-gun, Tochigi, Japan.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Kato
authors.affiliation: Department of General Surgical Science (Surgery 1), Gunma University Graduate School, Maebashi, Gunma, Japan.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Kuwano
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary / Q000628:therapy; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000556:secondary / Q000628:therapy; D059248:Chemoradiotherapy; D018572:Disease-Free Survival; D000077143:Docetaxel; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000628:therapy; D016629:Esophagectomy / Q000009:adverse effects; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D008175:Lung Neoplasms / Q000556:secondary / Q000601:surgery*; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced / Q000188:drug therapy; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D011446:Prospective Studies; D015996:Survival Rate; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D009944:Organoplatinum Compounds; D043823:Taxoids; D016179:Granulocyte Colony-Stimulating Factor; D000077143:Docetaxel; C053989:nedaplatin; D005472:Fluorouracil